PARP1 and breast carcinoma: PARP inhibitors, such as olaparib, under the brand name Lynparza, and talazoparib, under the brand name Talzenna, have been approved for the management of advanced HER-2-negative breast cancer in individuals with a BRCA1 or BRCA2 mutation [28].